Market Overview

Senseonics & Glooko Announce Partnership on Integrated Diabetes Management


World's first long-term CGM system to be integrated with world's leading
diabetes management platform

Senseonics Holdings, Inc. (NYSE-American: SENS), a medical technology
company focused on the development and commercialization of
transformative glucose monitoring products, today announced a
partnership with Glooko,
, the leading diabetes data management company. The partnership
enables integration of the long-term Eversense® branded continuous
glucose monitoring (CGM) systems with Glooko's diabetes data management

The integration of these solutions will allow Eversense CGM data to be
synced into Glooko's platform directly from the Senseonics cloud.
Eversense users will be able to view historical glucose and related data
both in Glooko's Mobile and Web Apps and will continue to get real-time
readings from their Eversense Mobile Application. Healthcare
professionals may view their patients' data in the Glooko Population
Tracker in interactive reports alongside other data resident in Glooko.

"With this integration, users can consolidate their glucose data with
insulin, meals, medication and exercise to help them see glycemic
patterns more readily. Glooko allows our users to take full advantage of
both companies' platforms and the large amount of data from our
Eversense® and Eversense® XL systems," said Dr. Tim Goodnow, President
and CEO of Senseonics. "Partnering with an innovative platform like
Glooko fits with our strategy of giving people the tools to use all of
their health data to conveniently and confidently make actionable
lifestyle decisions."

For Glooko, the integration of the Eversense systems is the first
long-term sensor that will be compatible with their intelligent digital
health platform. Users of the Eversense systems will have the
opportunity to see how their glucose levels change over the long term
without having to estimate the impact of frequent sensor changeovers and
warm-up periods.

"We are thrilled to add Senseonics' breakthrough Eversense and Eversense
XL CGM data to our platform so that people with diabetes and clinicians
can access this valuable data in context in our reports online and via
mobile," said Russ Johannesson, Glooko's CEO. He continued, "Our cloud
integration with Senseonics gives users easy access to their glucose
data from the sensor, enabling them to make decisions based on their
glucose patterns."

The Eversense system has been integrated with Diasend in the EU since
2017. The companies expect implementation of the Eversense/Glooko data
integration to be by the end of the year. Learnings from this
partnership will benefit both organizations as they expand into insulin
titration and decision support tools.

This global agreement covers all markets where Glooko and the Eversense
Systems are currently available.

About Eversense

The Eversense® Continuous Glucose Monitoring (CGM) System is indicated
for continually measuring glucose levels in persons age 18 and older
with diabetes for up to 90 days. It is intended to complement, not
replace, fingerstick blood glucose monitoring. The sensor insertion and
removal is performed by a physician. The Eversense CGM System is a
prescription device; patients should talk to their doctor to learn more.
For important safety information, see

About Senseonics

Senseonics Holdings, Inc. is a medical technology company focused on the
design, development and commercialization of glucose monitoring products
designed to help people with diabetes confidently live their lives with
ease. Senseonics' first generation continuous glucose monitoring (CGM)
system, Eversense®, includes a small sensor, smart transmitter and
mobile application. Based on fluorescence sensing technology, the sensor
is designed to be inserted subcutaneously and communicate with the smart
transmitter to wirelessly transmit glucose levels to a mobile device.
After insertion, the sensor is designed to continually and accurately
measure glucose levels. For more information on Senseonics, please visit

About Glooko

Glooko provides insights into diabetes by enabling both people with
diabetes (PWDs) and their care teams with technology to understand and
manage diabetes care. Our self-management mobile app automatically
uploads data from devices including blood glucose meters, insulin pumps,
CGMs and several fitness and activity trackers — providing timely and
verified data and enabling PWDs and care teams to correlate it with
diet, exercise, medication and other data. We provide care teams with an
easy office data upload solution and a population health app so they can
support PWDs during and in-between office visits. Trusted by the world's
leaders in diabetes care, we are used by 7,000 clinics and over 1.5
million PWDs in 23 countries across 15 languages. Learn more by visiting

View Comments and Join the Discussion!
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at